What is Wedbush’s Estimate for AnaptysBio FY2029 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for AnaptysBio in a report issued on Monday, February 3rd. Wedbush analyst D. Nierengarten anticipates that the biotechnology company will post earnings of ($4.04) per share for the year. Wedbush has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

Other equities research analysts have also recently issued research reports about the company. Guggenheim cut their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Truist Financial cut their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Wells Fargo & Company cut their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday. They set an “outperform” rating and a $25.00 price target for the company. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Price Performance

AnaptysBio stock opened at $16.51 on Tuesday. AnaptysBio has a 12 month low of $12.51 and a 12 month high of $41.31. The business has a 50 day simple moving average of $17.23 and a 200-day simple moving average of $26.89. The stock has a market capitalization of $502.40 million and a PE ratio of -2.72.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

Institutional Trading of AnaptysBio

Large investors have recently bought and sold shares of the company. Values First Advisors Inc. acquired a new stake in AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC grew its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares during the last quarter. Point72 DIFC Ltd lifted its position in shares of AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of AnaptysBio in the third quarter valued at $229,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.